Inside the research

Revvity, Inc.

RVTY Research profile · latest available data

Price overview

$151.11

▲ +0.43 (+0.3%)

52w hi$151.11
52w lo$82.21
Vol1.94M
As of25 Sep 2026

The Verdict

Hold

Our score +0.30

Short+0.38
Medium+0.40
Long-0.05

computed 2026-09-27

Key fundamentals

Revvity, Inc.

Healthcare · Diagnostics & Research

Market cap$16.86B
Enterprise value$19.18B
Trailing P/E72.30x
Forward P/E25.64x
EV / EBITDA21.90x
P / S (ttm)5.79x
Profit margin8.2%
Return on equity3.2%
Revenue growth+1.3%
Earnings growth+1.2%
Debt / equity46.23

Layer Breakdown

LayerRawContribution
Fundamental+0.07
Sector+0.08
Technical+0.28
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

United States · www.revvity.com

Risk Metrics

Beta vs SPX1.12
Corr SPX0.47
Annual vol38.1%
Annual ret+17.5%
Sharpe0.46
Max DD-35.6%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$113.64
High / Low$145.00 / $90.00
Median$110.00
Analysts14
Strong Buy1
Buy6
Hold9
Sell0
Strong Sell0

Recent rating actions

2026-05-07Barclays→ Equal-Weight
2026-05-06TD Cowen→ Buy
2026-05-06Stifel→ Hold
2026-05-06JP Morgan→ Neutral
2026-05-04Baird→ Outperform
2026-04-14Goldman Sachs→ Neutral

Material Events

DateEvent8-K
2026-08-04Earnings Release, Other Material Event…read
2026-05-05Earnings Release, Other Material Event…read
2026-05-01Bylaws Amendment, Shareholder Vote…read
2026-02-02Earnings Release, Exhibitsread
2026-01-13Earnings Release, Reg FD Disclosureread
2025-10-27Earnings Release, Exhibitsread
2025-10-24Officer / Director Changeread
2025-07-28Earnings Release, Exhibitsread
2025-04-28Earnings Release, Exhibitsread
2025-04-25Bylaws Amendment, Shareholder Vote…read
2025-01-31Earnings Release, Exhibitsread
2025-01-13Earnings Release, Reg FD Disclosureread

Flow & Concentration

Insider 180d net$0
Insider buys / sells0 / 0
Insider biasNeutral
13F holders8
Top-5 share98.7%
HHI3,520 (concentrated)

Top Holders

HolderValueShares
State Street Corp$483.17M4.34M
Capital Research / Capital World$207.44M1.86M
Citadel Advisors$165.57M1.49M
Fidelity / FMR LLC$51.81M465.64K
AQR Capital Management$13.96M125.49K
Millennium Management$8.37M75.23K
Bridgewater Associates$2.69M24.16K
T. Rowe Price Group$615.36K5.53M

As of 2026-06-30

Dividends

Yield (TTM)0.14%
$ / share (TTM)$0.21
5y CAGR+0.0%

Annual dividend per share

2021$0.28
2022$0.28
2023$0.28
2024$0.28
2025$0.28
2026$0.14

SEC Filings

DateFormDoc
2026-08-1110-Qview
2026-08-048-Kview
2026-07-224view
2026-06-2311-Kview
2026-06-174view
2026-05-1210-Qview
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view
2026-05-114view

The Long Run

FY 2010–2025 · 16 years

LineLatestCAGRTrend
Revenue$2.86B+3.5%
Gross profit$693.19M+13.2%
Operating income$300.56M+4.9%
Net income$693.09M+15.0%
Cash from ops$582.93M+9.5%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$150.70$151.99$147.03$151.111.94M
Sep 24$141.79$152.26$141.79$150.682.54M
Sep 23$142.40$145.00$140.08$142.112.24M
Sep 22$143.12$144.77$141.71$143.312.87M
Sep 21$144.53$145.55$142.30$143.592.06M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →